For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and ...
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be ...
With the FDA clearance of an investigational new drug application for SynKIR-310, a phase 1 trial evaluating the agent in ...
Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.
In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of ...
Currently, carboplatin or cisplatin with etoposide combined with atezolizumab (Tecentriq) or durvalumab (Imfinzi) followed by ...
A US health care executive survey found 30% see health equity solely as a social concern. Yet, it's about ensuring everyone has a fair shot at optimal health. Utilizing standardized data can shift ...
SNB-101, a nanoparticle drug for small cell lung cancer, received a fast track designation from the FDA for expedited ...
Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III ...
Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding ...
IGV-001 is an autologous cell immunotherapy with antisense oligonucleotide targeting IGF-1R. In the phase 1b study, IGV-001 ...
The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results